Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Nolan Stevaux, Olivier ^a   Zhong, Wendy ^a   Culp, Stacey ^b   Shaffer, Kathy ^b   Hoover, Joseph ^b   Wickramasinghe, Dineli ^a   Ruefli Brasse, Astrid ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 9; ENDOGLIN; ENDOGLIN ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD8 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; INTRACELLULAR SIGNALING; NONHUMAN; PAI 1 GENE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT; SERPINE1 GENE; SMAD6 GENE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; GROWTH DIFFERENTIATION FACTORS; HUMANS; MICE; PHOSPHORYLATION; PROTEIN BINDING; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871655253     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050920     Document Type: Article

References (53)

1. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, et al. (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clinical Cancer Research 14: 1931-1937.
2. Nolan-Stevaux O, Jun HT (2012) Beyond VEGF: the Notch and ALK1 signaling pathways as tumor angiogenesis targets. In: Ran S, editor. Tumor Angiogenesis. 1 ed: Intech Open Access. 85-114.
3. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, et al. (2011) Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth. J Biol Chem 286: 30034-30046.
4. Bernabeu C, Lopez-Novoa JM, Quintanilla M, (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 1792: 954-973.
5. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, et al. (1999) Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537.
6. Urness LD, Sorensen LK, Li DY, (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26: 328-331.
7. Bailly S, (2008) HHT is not a TGFb disease. Blood 111: 478.
8. Sorensen LK, Brooke BS, Li DY, Urness LD, (2003) Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev Biol 261: 235-250.
9. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, et al. (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204: 574-584.
10. Koleva RI, Conley BA, Romero D, Riley KS, Marto JA, et al. (2006) Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J Biol Chem 281: 25110-25123.
11. Lamouille S, Mallet C, Feige JJ, Bailly S, (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100: 4495-4501.
12. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S, (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
13. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, et al. (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030.
14. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P, et al. (1994) Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 1995-2001.
15. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, et al. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753.
16. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, et al. (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23: 4018-4028.
17. Lebrin F, Mummery CL, (2008) Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 18: 25-32.
18. ten Dijke P, Arthur HM, (2007) Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869.
19. Lopez-Novoa JM, Bernabeu C, (2010) The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 299: H959-974.
20. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, et al. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120: 964-972.
21. Brown MA, Zhao Q, Baker KA, Naik C, Chen C, et al. (2005) Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 280: 25111-25118.
22. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, et al. (2010) ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9: 379-388.
23. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, et al. (2008) Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circulation Research 102: 914-922.
24. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, et al. (2010) Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 207: 85-100.
25. Pardali E, Goumans MJ, ten Dijke P, (2010) Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 20: 556-567.
26. Cunha SI, Pietras K (2011) ALK1 as an emerging target for anti-angiogenic therapy for cancer. Blood 117 (15).
27. van Meeteren LA, Goumans MJ, Ten Dijke P, (2011) TGF-beta Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy. Curr Pharm Biotechnol 12: 2108-2120.
28. Upton PD, Davies RJ, Trembath RC, Morrell NW, (2009) Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 284: 15794-15804.
29. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, et al. (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv 8: 135-143.
30. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, et al. (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3: 335-344.
31. Evensen L, Micklem DR, Blois A, Berge SV, Aarsaether N, et al. (2009) Mural cell associated VEGF is required for organotypic vessel formation. PLoS One 4: e5798.
32. David L, Feige JJ, Bailly S, (2009) Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 20: 203-212.
33. van Meeteren LA, Ten Dijke P (2011) Regulation of endothelial cell plasticity by TGF-beta. Cell Tissue Res.
34. Shao ES, Lin L, Yao Y, Bostrom KI, (2009) Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114: 2197-2206.
35. Morris E, Chrobak I, Bujor A, Hant F, Mummery C, et al. (2011) Endoglin promotes TGF-beta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 226: 3340-3348.
36. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, et al. (2009) TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J 28: 88-98.
37. Daly AC, Randall RA, Hill CS, (2008) Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28: 6889-6902.
38. Wrighton KH, Lin X, Yu PB, Feng XH, (2009) Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors. J Biol Chem 284: 9755-9763.
39. van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Gallo Stampino C, et al. (2012) Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting. J Biol Chem 287: 18551-18561.
40. Bostrom K, Zebboudj AF, Yao Y, Lin TS, Torres A, (2004) Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem 279: 52904-52913.
41. Massague J, (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178.
42. Gazit-Bornstein G, Laing N, Barry ST, Babcook J, Zhou Q (2010) Antibodies directed to CD105 and uses thereof. In: USPTO, editor. USA: MedImmune LLC, Gaithersburg, MD.
43. Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M, (1999) Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 8: 2171-2181.
44. Fernandez LA, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Hebbel RP, et al. (2005) Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 68: 235-248.
45. Duwel A, Eleno N, Jerkic M, Arevalo M, Bolanos JP, et al. (2007) Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumour Biol 28: 1-8.
46. Bourdeau A, Dumont DJ, Letarte M, (1999) A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104: 1343-1351.
47. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, et al. (2008) Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 122: 2266-2273.
48. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, et al. (2012) A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. Clin Cancer Res 18: 4820-4829.
49. Bidart M, Ricard N, Levet S, Samson M, Mallet C, et al. (2012) BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci 69: 313-324.
50. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RS, et al. (1995) Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1: 129-136.
51. Llorca O, Trujillo A, Blanco FJ, Bernabeu C, (2007) Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J Mol Biol 365: 694-705.
52. Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ, et al. (2012) Structural and functional insights into endoglin ligand recognition and binding. PLoS One 7: e29948.
53. She X (2003) Ph.D. Thesis: Positional and Functional Epitope Mapping of Endoglin, a Proliferation-associated Antigen of Human Endothelial Cells: State University of New York at Buffalo.